H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Oct 1;1154:122288. doi: 10.1016/j.jchromb.2020.122288. Epub 2020 Jul 29.
In order to undertake an epidemiologic study relating levels of parent estrogens (estrone and estradiol) and estrogen metabolites (EMs) to other breast cancer risk factors, we have optimized methods for EM quantification with ultra high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS). A two-step approach was adopted; the first step comprised method development and evaluation of the method performance. The second step consisted of applying this method to quantify estrogens in postmenopausal women and determine if the observed patterns are consistent with the existing literature and prior knowledge of estrogen metabolism. First, 1-methylimidazole-2-sulfonyl chloride (MIS) was used to derivatize endogenous estrogens and estrogen metabolites in urine from study participants. Since C18 reversed phase columns have not been able to separate all the structurally related EMs, we used a C18-pentafluorophenyl (PFP) column. The parent estrogens and EMs were baseline resolved with distinct retention times on this C18-PFP column using a 30 min gradient. This method was used to quantify the parent estrogens and 13 EMs in urine samples collected in an initial pilot study involving males as well as pre- and peri-menopausal females to assess a range of EM levels in urine samples and enable comparison to the previous literature for assay evaluation. Detection limits ranged from 1 - 20 pg/mL depending on the EM. We evaluated matrix effects and interference as well as the intra- and inter-batch reproducibility including hydrolysis, extraction, derivatization and LC-MS analysis using charcoal-stripped human urine as a matrix. Methods were then applied to the measurement of estrogens in urine samples from 169 postmenopausal women enrolled in an epidemiological study to examine relationships between breast cancer risk, the intestinal microbiome, and urinary EMs. The results from our cohort are comparable to previous reports on urinary EMs in postmenopausal women and enabled thorough evaluation of the method.
为了开展一项与父母雌激素(雌酮和雌二醇)和雌激素代谢物(EMs)水平相关的流行病学研究,并将其与其他乳腺癌危险因素联系起来,我们已经优化了使用超高效液相色谱-高分辨率质谱(UHPLC-HRMS)定量 EM 的方法。我们采用了两步法;第一步包括方法开发和方法性能评估。第二步包括应用该方法定量绝经后妇女的雌激素,并确定观察到的模式是否与现有文献和雌激素代谢的先前知识一致。首先,1-甲基咪唑-2-磺酰氯(MIS)用于衍生研究参与者尿液中的内源性雌激素和雌激素代谢物。由于 C18 反相柱不能分离所有结构相关的 EMs,我们使用 C18-五氟苯基(PFP)柱。在该 C18-PFP 柱上,使用 30 分钟梯度,通过独特的保留时间基线分离母体雌激素和 EMs。该方法用于定量初始男性和绝经前及围绝经期女性参与的初步试点研究中收集的尿液样本中的母体雌激素和 13 种 EM,以评估尿液样本中 EM 水平的范围,并对测定进行评估,与之前的文献进行比较。检测限取决于 EM,范围为 1-20 pg/mL。我们评估了基质效应和干扰以及批内和批间重现性,包括水解、提取、衍生化和 LC-MS 分析,使用活性炭提取的人尿液作为基质。然后将方法应用于 169 名绝经后妇女的尿液样本中雌激素的测量,以研究乳腺癌风险、肠道微生物组和尿液 EMs 之间的关系。我们队列的结果与绝经后妇女尿液 EMs 的先前报告相当,并能够对该方法进行全面评估。